Posted by Michael Wonder on 07 Oct 2021
ICER publishes evidence report on mavacamten for hypertrophic cardiomyopathy
7 October 2021 - Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for patients over the long term; using patient outcomes from short-term studies, treatment would achieve common thresholds for cost effectiveness if priced lower than $15,000 per year.
The Institute for Clinical and Economic Review today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.
